Director converts preferred into common at 20/20 Biolabs (AIDX)

Rhea-AI Filing Summary

20/20 Biolabs, Inc. director John G. Compton reported an automatic conversion of preferred stock into common stock. On February 19, 2026, 7,669 shares of Series A-2 preferred stock converted into 7,669 shares of common stock at a stated price of $0.00 per share upon the listing of the company’s common stock on the Nasdaq Capital Market. After this derivative conversion, Compton directly held 14,335 shares of common stock.

Insider Trade Summary

7,669 shares exercised/converted

Mixed 2 txns

Insider Compton John G.

Role Director

Type	Security	Shares	Price	Value
Conversion	Series A-2 Preferred Stock	7,669	$0.00	--
Conversion	Common Stock	7,669	$0.00	--

Holdings After Transaction: Series A-2 Preferred Stock — 0 shares (Direct); Common Stock — 14,335 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/23/2026 - 06:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Compton John G.

(Last) (First) (Middle)

C/O 20/20 BIOLABS, INC.

15810 GAITHER ROAD, SUITE 235

(Street)

GAITHERSBURG MD 20877

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
20/20 Biolabs, Inc. [ AIDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		C(1)		7,669	A	$0	14,335	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A-2 Preferred Stock(1)	(1)	02/19/2026		C(1)			7,669	(1)	(1)	Common Stock	7,669	(1)	0	D

Explanation of Responses:

1. On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.

	/s/ John G. Compton	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AIDX director John G. Compton report?

John G. Compton reported an automatic conversion of 7,669 Series A-2 preferred shares into 7,669 common shares. This derivative conversion occurred on February 19, 2026, at a stated price of $0.00 per share, tied to the Nasdaq Capital Market listing.

Did John G. Compton buy or sell AIDX shares in this filing?

He neither bought nor sold shares in an open-market trade. The filing shows a derivative conversion, where 7,669 Series A-2 preferred shares automatically became 7,669 common shares upon Nasdaq listing, without a cash purchase or sale transaction.

How many AIDX common shares does John G. Compton own after this transaction?

After the conversion, John G. Compton directly owned 14,335 shares of 20/20 Biolabs common stock. This total reflects the addition of 7,669 common shares received from converting his Series A-2 preferred shares on February 19, 2026.

What triggered the conversion of AIDX Series A-2 preferred stock reported by Compton?

The conversion was automatically triggered by the listing of 20/20 Biolabs’ common stock on the Nasdaq Capital Market. At that point, all Series A-2 preferred shares held by Compton converted into an equivalent number of common shares, as described in the footnote.

Was there an expiration date on the AIDX Series A-2 preferred stock converted by Compton?

The Series A-2 preferred stock held by John G. Compton had no expiration date. Instead of expiring, all such shares automatically converted into common stock when the company’s common shares were listed on the Nasdaq Capital Market on February 19, 2026.

What does the Form 4 derivative conversion for AIDX indicate about Compton’s holdings?

The derivative conversion indicates Compton’s economic interest shifted from preferred to common stock without a cash trade. He exchanged 7,669 preferred shares for 7,669 common shares, ending with 14,335 common shares directly owned after the Nasdaq listing event.